Bridget Silverman
Senior Editor
Latest From Bridget Silverman
Vaxneuvance, Prevnar 20 Earn CDC Cmte Nod For Age- And Risk-Based Use; Broader Shingrix Use Supported
ACIP votes unanimously to recommend Merck and Pfizer’s pneumococcal vaccines in elderly and immunocompromised adults; GSK’s herpes zoster vaccine also gets unanimous nod for immunocompromised adults.
Vaccines’ Second Shift: CDC Nod Tends To Follow US FDA OK By Almost Nine Months
New vaccines’ journey to market has another stage after FDA approval: CDC and its Advisory Committee on Immunization Practices. In advance of the ACIP’s October meeting, a Pink Sheet infographic follows vaccines approved by the FDA over the last six years through ACIP to the commercially vital recommendation by CDC.
Earlier-Stage Approvals For Tecentriq, Keytruda, Verzenio Underscore Broader Oncology Trends
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Orphans Dominate New US FDA Approvals, Thanks To Rethymic, Tavneos, And Livmarli
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s October Outlook Includes Psoriasis Blockbuster Hopeful, Ophthalmology And Orphans
User fee goal dates are coming up in October for more than 15 applications, according to the Pink Sheet’s US FDA Performance Tracker.
Keeping Track: US FDA Is Approving JAK Inhibitors Again, Starting With Incyte’s Opzelura; Seagen’s Tivdak Cleared
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.